Repligen Corp

RGEN

Company Profile

  • Business description

    Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.

  • Contact

    41 Seyon Street
    Building 1, Suite 100
    WalthamMA02453
    USA

    T: +1 781 250-0111

    E: [email protected]

    https://www.repligen.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Instruments & Supplies

    Fiscal Year End

    31 December 2026

    Employees

    2,000

Stocks News & Analysis

stocks

Undervalued ASX share retains wide moat rating despite regulatory pressures

Proposed price regulation impacts our fair value.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Tesla: Shares fall as deliveries come in below consensus

Long-term growth less reliant on auto sales.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.702.000.02%
CAC 408,263.87355.134.49%
DAX 4024,080.631,159.045.06%
Dow JONES (US)47,819.421,234.962.65%
FTSE 10010,608.88260.092.51%
HKSE25,893.02776.493.09%
NASDAQ22,673.78655.932.98%
Nikkei 22556,308.422,878.865.39%
NZX 50 Index13,253.94184.281.41%
S&P 5006,781.44164.592.49%
S&P/ASX 2008,951.8021.00-0.23%
SSE Composite Index3,995.00104.832.69%

Market Movers